| Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ... Journal of hepatology 71 (6), 1175-1183, 2019 | 75 | 2019 |
| Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, ... Scientific reports 9 (1), 1-14, 2019 | 70 | 2019 |
| 1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages A Casadei-Gardini, L Del Coco, G Marisi, F Conti, G Rovesti, P Ulivi, ... Cancers 12 (1), 241, 2020 | 57 | 2020 |
| Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy F Rossignoli, G Grisendi, C Spano, G Golinelli, A Recchia, G Rovesti, ... Cancer Gene Therapy 26 (1), 11-16, 2019 | 57 | 2019 |
| MSC-delivered soluble TRAIL and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma F Rossignoli, C Spano, G Grisendi, EM Foppiani, G Golinelli, I Mastrolia, ... Theranostics 9 (2), 436, 2019 | 56 | 2019 |
| Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board G Rovesti, F Valoriani, M Rimini, C Bardasi, R Ballarin, F Di Benedetto, ... Nutrients 13 (10), 3522, 2021 | 40 | 2021 |
| Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience G Rovesti, G Orsi, A Kalliopi, C Vivaldi, G Marisi, L Faloppi, FG Foschi, ... Gastrointestinal Tumors 6 (3-4), 92-107, 2019 | 37 | 2019 |
| ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib G Marisi, E Petracci, F Raimondi, L Faloppi, FG Foschi, G Lauletta, ... Cancers 11 (7), 1023, 2019 | 31 | 2019 |
| Liquid biopsy in hepatocellular carcinoma: opportunities and challenges for immunotherapy P Maravelia, DN Silva, G Rovesti, M Chrobok, P Stål, YC Lu, A Pasetto Cancers 13 (17), 4334, 2021 | 25 | 2021 |
| Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial A Casadei Gardini, E Scarpi, M Valgiusti, M Monti, S Ruscelli, L Matteucci, ... Therapeutic Advances in Medical Oncology 12, 1758835920958363, 2020 | 25 | 2020 |
| Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the Bagnacavallo population study M Rimini, A Casadei-Gardini, A Ravaioli, G Rovesti, F Conti, A Borghi, ... Journal of clinical medicine 9 (4), 1177, 2020 | 25 | 2020 |
| Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib A Casadei-Gardini, G Rovesti, V Dadduzio, C Vivaldi, E Lai, S Lonardi, ... HPB 23 (6), 915-920, 2021 | 17 | 2021 |
| Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma G Orsi, F Tovoli, V Dadduzio, C Vivaldi, O Brunetti, L Ielasi, F Conti, ... Targeted Oncology 15 (6), 773-785, 2020 | 17 | 2020 |
| Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study A Casadei-Gardini, G Marisi, V Dadduzio, L Gramantieri, L Faloppi, P Ulivi, ... Clinical Cancer Research 26 (17), 4485-4493, 2020 | 16 | 2020 |
| Effects of metformin and vitamin D on clinical outcome in cholangiocarcinoma patients A Casadei-Gardini, R Filippi, M Rimini, IG Rapposelli, L Fornaro, ... Oncology 99 (5), 292-299, 2021 | 15 | 2021 |
| BRCA in gastrointestinal cancers: current treatments and future perspectives E Molinaro, K Andrikou, A Casadei-Gardini, G Rovesti Cancers 12 (11), 3346, 2020 | 13 | 2020 |
| Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib A Casadei-Gardini, V Dadduzio, G Rovesti, G Cabibbo, R Vukotic, ... Medicine 99 (22), e19958, 2020 | 13 | 2020 |
| First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? C Vivaldi, F Salani, G Rovesti, I Pecora, S Catanese, A Casadei-Gardini, ... European Journal of Cancer 137, 108-116, 2020 | 11 | 2020 |
| Process development for adoptive cell therapy in academia: a pipeline for clinical-scale manufacturing of multiple TCR-T cell products DN Silva, M Chrobok, G Rovesti, K Healy, AK Wagner, P Maravelia, ... Frontiers in Immunology, 2842, 0 | 11 | |
| The growing skyline of advanced hepatocellular carcinoma treatment: a review FM Schipilliti, I Garajová, G Rovesti, R Balsano, F Piacentini, M Dominici, ... Pharmaceuticals 14 (1), 43, 2021 | 10 | 2021 |
